296 assets in Myelodysplastic Syndrome

Therapeutic assets addressing Myelodysplastic Syndrome, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Vedolizumab Myelodysplastic Syndrome	City of Hope Medical Center	P3	CCC (54)
Alpha/Beta T Cell-Depleted Hematopoietic Stem Cells Myelodysplastic Syndrome	Masonic Cancer Center, University of Minnesota	P2	CCC (53)
Blinatumomab Myelodysplastic Syndrome	St. Jude Children's Research Hospital	P2	CCC (53)
cd45ra-depleted dli Myelodysplastic Syndrome	St. Jude Children's Research Hospital	P2	CCC (53)
Mgta-456 Myelodysplastic Syndrome	Masonic Cancer Center, University of Minnesota	P2	CCC (53)
Monalizumab Myelodysplastic Syndrome	Istituto Clinico Humanitas	P2	CCC (53)
Ptcy Myelodysplastic Syndrome	Center for International Blood and Marrow Transplant Research	P2	CCC (53)
shr2554 Myelodysplastic Syndrome	The First Affiliated Hospital of Soochow University	P2	CCC (53)
Vibecotamab Myelodysplastic Syndrome	M.D. Anderson Cancer Center	P2	CCC (53)
Dexrazoxane Myelodysplastic Syndrome	Andrew E. Place, MD	P2	CCC (52)
Erwinia L-Asparaginase Myelodysplastic Syndrome	Andrew E. Place, MD	P2	CCC (52)
Human Immunoglobulins Myelodysplastic Syndrome	Center for International Blood and Marrow Transplant Research	P2	CCC (52)
Letermovir Myelodysplastic Syndrome	City of Hope Medical Center	P2	CCC (52)
Multi-Peptide Cmv-Modified Vaccinia Ankara Vaccine Myelodysplastic Syndrome	City of Hope Medical Center	P2	CCC (52)
Recombinant Human Granulocyte Colony-Stimulating Factor Myelodysplastic Syndrome	City of Hope Medical Center	P2	CCC (52)
BX2 Myelodysplastic Syndrome	Institut Paoli-Calmettes	P2	CCC (51)
bx3 Myelodysplastic Syndrome	Institut Paoli-Calmettes	P2	CCC (51)
BX4 Myelodysplastic Syndrome	Institut Paoli-Calmettes	P2	CCC (51)
Degarelix Myelodysplastic Syndrome	Memorial Sloan Kettering Cancer Center	P2	CCC (51)
Ebx-102 Myelodysplastic Syndrome	Imperial College London	P2	CCC (51)
Fedratinib Myelodysplastic Syndrome	University of Washington	P2	CCC (51)
Gardasil 9 Vaccine Myelodysplastic Syndrome	Vastra Gotaland Region	P2	CCC (51)
Interferon Gamma-1B Myelodysplastic Syndrome	Sawa Ito, MD	P2	CCC (51)
NK-92 Myelodysplastic Syndrome	M.D. Anderson Cancer Center	P2	CCC (51)
Pacritinib Myelodysplastic Syndrome	University of Washington	P2	CCC (51)
Pbsc Myelodysplastic Syndrome	Fred Hutchinson Cancer Center	P2	CCC (51)
Pembrolizumab Myelodysplastic Syndrome	City of Hope Medical Center	P1	CCC (51)
Rimiducid Myelodysplastic Syndrome	Fred Hutchinson Cancer Center	P2/3	CCC (51)
tcb008 Myelodysplastic Syndrome	TC Biopharm	P2	CCC (51)
Baricitinib Myelodysplastic Syndrome	Federal Research Institute of Pediatric Hematology, Oncology and Immunology	P2/3	CCC (50)
Dilanubicel Myelodysplastic Syndrome	Fred Hutchinson Cancer Center	P2	CCC (50)
Ocifisertib Myelodysplastic Syndrome	Treadwell Therapeutics, Inc	P1/2	CCC (49)
Cephalotaxine 4-Methyl (2R)-2-Hydroxy-2-(4-Hydroxy-4-Methylpentyl)Butanedioate (Ester) Myelodysplastic Syndrome	M.D. Anderson Cancer Center	P1/2	CCC (48)
Cytokine-Induced Memory-Like Nk Cells Myelodysplastic Syndrome	Washington University School of Medicine	P2	CCC (48)
Dna, D(3'-Amino-3'-Deoxy-P-Thio)(T-A-G-G-G-T-T-A-G-A-C-A-A), 5'-(O-(2-Hydroxy-3-((1-Oxohexadecyl)Amino)Propyl) Hydrogen Phosphorothioate) Myelodysplastic Syndrome	GCP-Service International West GmbH	P2	CCC (48)
E-7820 Myelodysplastic Syndrome	Memorial Sloan Kettering Cancer Center	P2	CCC (48)
Elranatamab Myelodysplastic Syndrome	CellCentric Ltd.	P1/2	CCC (48)
Filgrastim-Sndz Myelodysplastic Syndrome	M.D. Anderson Cancer Center	P2	CCC (48)
Immunoglobulin G1, Anti-(Human Interleukin-1 Receptor Accessory Protein) (Human-Mus Musculus Monoclonal Can04 .Gamma.1-Chain), Disulfide With Human-Mus Musculus Monoclonal Can04 .Kappa.-Chain, Dimer Myelodysplastic Syndrome	M.D. Anderson Cancer Center	P1/2	CCC (48)
Inobrodib Myelodysplastic Syndrome	CellCentric Ltd.	P1/2	CCC (48)
Lapine T-Lymphocyte Immune Globulin Myelodysplastic Syndrome	Children's Oncology Group	P3	CCC (48)
Mercaptopurine Anhydrous Myelodysplastic Syndrome	Haukeland University Hospital	P1/2	CCC (48)
Pegfilgrastim Myelodysplastic Syndrome	M.D. Anderson Cancer Center	P1/2	CCC (48)
Retinol Myelodysplastic Syndrome	St. Petersburg State Pavlov Medical University	P2	CCC (48)
Teclistamab Myelodysplastic Syndrome	CellCentric Ltd.	P1/2	CCC (48)
Tranexamic Acid Myelodysplastic Syndrome	University of Manitoba	P2	CCC (48)
Venclyxto Myelodysplastic Syndrome	First Affiliated Hospital of Zhejiang University	P2	CCC (48)
ard103 Myelodysplastic Syndrome	ARCE Therapeutics, Inc.	P1/2	CC (47)
Car.70/Il15-Transduced Cb-Nk Cells Myelodysplastic Syndrome	M.D. Anderson Cancer Center	P1/2	CC (47)
Itacitinib Myelodysplastic Syndrome	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	P2	CC (47)

Showing 101 to 150 of 296 assets

PreviousPage 3 of 6Next